The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.
Dana E. Rathkopf
No relevant relationships to disclose
Matthew Raymond Smith
Consultant or Advisory Role - Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar); Johnson & Johnson; Johnson & Johnson
Research Funding - Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar); Johnson & Johnson
Johann Sebastian De Bono
Employment or Leadership Position - The Institute of Cancer Research ; The Institute of Cancer Research ; The Institute of Cancer Research
Consultant or Advisory Role - Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Dendreon; Dendreon; Dendreon; Enzon; Enzon; Enzon; Exelixis; Exelixis; Exelixis; Genentech; Genentech; Genentech; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Janssen R&D; Janssen Research & Development; Janssen Research & Development; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Medivation; Medivation; Medivation; Merck; Merck; Merck; Novartis; Novartis; Novartis; Ortho Biotech; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Sanofi ; Sanofi ; Sanofi ; SuperGen; SuperGen; SuperGen; Takeda; Takeda; Takeda
Honoraria - Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
Research Funding - AstraZeneca; AstraZeneca
Other Remuneration - Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Dendreon; Dendreon; Dendreon; Enzon; Enzon; Enzon; Exelixis; Exelixis; Exelixis; Genentech; Genentech; Genentech; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Medivation; Medivation; Medivation; Merck; Merck; Merck; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Sanofi ; Sanofi ; Sanofi ; SuperGen; SuperGen; SuperGen; Takeda; Takeda; Takeda
Christopher Logothetis
Consultant or Advisory Role - Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar); Johnson & Johnson
Honoraria - Johnson & Johnson; Johnson & Johnson
Research Funding - Johnson & Johnson; Johnson & Johnson
Other Remuneration - Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar)
Neal D. Shore
No relevant relationships to disclose
Paul L. De Souza
Employment or Leadership Position - Lilly; Lilly Australia
Consultant or Advisory Role - Janssen; Janssen Australia; Janssen Pharmaceutical ; Janssen Pty Ltd; Pfizer; Sanofi ; Sanofi Australia
Research Funding - Novogen; Novogen Australia
Karim Fizazi
Consultant or Advisory Role - Amgen; Amgen; Astellas/Medivation; Astellas/Medivation; AstraZeneca; AstraZeneca; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Dendreon; Dendreon; Exelixis; Exelixis; Ipsen; Ipsen; Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar); Keocyt; Keocyt; Millennium; Millennum/Takeda; Novartis; Novartis; Sanofi ; Sanofi
Honoraria - Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar); Janssen-Cilag
Research Funding - Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar)
Peter Mulders
Consultant or Advisory Role - Amgen; Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bayer; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer
Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; GlaxoSmithKline; GlaxoSmithKline
Research Funding - Bayer; Bayer
Other Remuneration - Johnson & Johnson; Johnson & Johnson
Paul N. Mainwaring
Consultant or Advisory Role - Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar)
John D. Hainsworth
Research Funding - Johnson & Johnson; Johnson & Johnson; Medivation; Medivation
Tomasz M. Beer
Research Funding - Janssen Pharmaceutical ; Janssen Pharmaceuticals
Scott A. North
Consultant or Advisory Role - Abraxis BioScience; Abraxis BioScience; Amgen; Amgen; AstraZeneca; AstraZeneca; GlaxoSmithKline; GlaxoSmithKline; Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar); Novartis; Novartis; Pfizer; Pfizer; Sanofi ; Sanofi
Honoraria - Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar); Novartis; Novartis
Yves Fradet
Honoraria - Janssen Research & Development; Janssen-Ortho
Research Funding - Janssen Research & Development; Janssen-Ortho
Thomas W. Griffin
Employment or Leadership Position - Janssen R&D; Janssen Research & Development
Stock Ownership - Johnson & Johnson; Johnson & Johnson
Youn Choi Park
Employment or Leadership Position - Janssen R&D; Janssen Research & Development
Stock Ownership - Johnson & Johnson; Johnson & Johnson
Thian San Kheoh
Employment or Leadership Position - Janssen R&D; Janssen Research & Development
Stock Ownership - Johnson & Johnson; Johnson & Johnson
Eric Jay Small
No relevant relationships to disclose
Howard I. Scher
Consultant or Advisory Role - Amgen; Amgen; Aragon Pharmaceuticals; Aragon Pharmaceuticals; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Dendreon; Dendreon; Enzon; Enzon; Exelixis; Exelixis; Janssen Global Services; Janssen Pharmaceutical ; Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar); Medivation; Medivation; Millennium; Millennium; Novartis; Novartis; Sanofi ; Sanofi
Stock Ownership - Genta; Johnson & Johnson; Johnson & Johnson
Honoraria - Amgen; Amgen; Centocor Ortho Biotech; Centocor Ortho Biotech; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar); Millennium; Millennium; Novartis; Novartis; Orion/Endo; Orion/Endo; Sanofi ; Sanofi
Research Funding - Aragon Pharmaceuticals; Aragon Pharmaceuticals; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar); Medivation; Medivation; Veridex; Veridex
Other Remuneration - Amgen; Amgen; AstraZeneca; AstraZeneca; Exelixis; Exelixis; Janssen Research & Development; Janssen Research & Development (formerly Ortho Biotech Oncology R&D, formerly Cougar); Medivation; Medivation; Millennium; Millennium; Novartis; Novartis; Orion/Endo; Orion/Endo; Sanofi ; Sanofi
Arturo Molina
Employment or Leadership Position - Janssen R&D; Janssen Research & Development
Stock Ownership - Johnson & Johnson; Johnson & Johnson
Charles J. Ryan
No relevant relationships to disclose